Drug Trial Radar · NCT00073528
Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer
Last checked: Nov 20, 2026Latest source record: Feb 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,286
Actual
Start
Dec 9, 2003
Primary completion
Jun 3, 2008
Study completion Mar 22, 2018
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 26, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluated and compared the efficacy and tolerability of lapatinib and letrozole, with letrozole and placebo in post-menopausal women with hormone receptor positive (ER positive and/or PgR positive) advanced or metastatic breast cancer, who had not received prior therapy for advanced or metastatic disease.
Conditions
- Breast Neoplasms
Interventions
LapatinibDrug
1500 mg orally once a day
LetrozoleDrug
2.5 mg orally once a day
PlaceboDrug
Placebo (which matched with lapatinib tablet)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Progression Free Survival (PFS) in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced or Metastatic Breast Cancer as Assessed by the InvestigatorTime frame: From the date of randomization until the date of the first documented progression or date of death from any cause, whichever came first, assessed for up to 46 months
- Progression Free Survival (PFS) of Participants in the HER2-Positive Population as Assessed by the InvestigatorTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 46 months
Locations
278 sites in 29 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Tucson, Arizona
Novartis Investigative Site
Hot Springs, Arkansas
Novartis Investigative Site
Jonesboro, Arkansas
Novartis Investigative Site
Alhambra, California
Novartis Investigative Site
Bakersfield, California
Novartis Investigative Site
Duarte, California
Novartis Investigative Site
Fountain Valley, California
Novartis Investigative Site
Fresno, California
Novartis Investigative Site
Fullerton, California
Novartis Investigative Site
La Jolla, California
Novartis Investigative Site
Long Beach, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Montebello, California
Novartis Investigative Site
Northridge, California
Novartis Investigative Site
Oxnard, California
Novartis Investigative Site
Pleasant Hill, California
Novartis Investigative Site
Porterville, California
Novartis Investigative Site
Redondo Beach, California
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
Santa Barbara, California
Novartis Investigative Site
Santa Maria, California
Novartis Investigative Site
Vallejo, California
Novartis Investigative Site
Vista, California
Novartis Investigative Site
Aurora, Colorado
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
Longmont, Colorado
Novartis Investigative Site
Wheat Ridge, Colorado
Novartis Investigative Site
New Haven, Connecticut
Novartis Investigative Site
Boca Raton, Florida
Novartis Investigative Site
Boca Raton, Florida
Novartis Investigative Site
Gainesville, Florida
Novartis Investigative Site
Gainesville, Florida
Novartis Investigative Site
Hollywood, Florida
Novartis Investigative Site
Lakeland, Florida
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Orlando, Florida
Novartis Investigative Site
Port Saint Lucie, Florida
Novartis Investigative Site
West Palm Beach, Florida
Novartis Investigative Site
Atlanta, Georgia
Novartis Investigative Site
Marietta, Georgia
Showing 40 of 278 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.